Melior Receives NOA From USPTO For Diabetes, Obesity Drug Candidate
The patent will cover use of MLR-1023 for the treatment of type II diabetes, obesity and metabolic syndrome, including its use in combination with other compounds and as
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.
proinnovera offers a full range of clinical research services for Phase I-IV clinical trials throughout Europe. proinnovera offers expertise in several therapeutic areas including dermatology, pain management, allergy/respiratory,